Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × rilotumumab × Clear all
NCT00791154 2024-08-23

SCLC

NantCell, Inc.

Phase 1/2 Terminated
213 enrolled 16 charts
Thoracic

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01233687 2017-06-22

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

University of Pittsburgh

Phase 1/2 Completed
49 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡